XML 59 R49.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Stock-based compensation expense $ 11,309   $ 7,770   $ 28,421 $ 16,556
Depreciation expense         72 93
Net loss (83,720) $ (92,561) (71,127) $ (69,296) (176,281) (140,423)
Reportable Segment            
Segment Reporting [Line Items]            
Personnel-related expenses 18,943   11,913   36,673 24,943
Stock-based compensation expense 11,309   7,770   28,421 16,556
Depreciation expense 33   46   72 93
Other segment expenses 12,851   6,753   24,940 15,129
Other income, net 13,184   4,940   26,483 10,372
Net loss (83,720)   (71,127)   (176,281) (140,423)
Reportable Segment | Ulixacaltamide            
Segment Reporting [Line Items]            
Program-specific expenses 13,299   18,385   32,402 41,898
Reportable Segment | Vormatrigine            
Segment Reporting [Line Items]            
Program-specific expenses 12,878   17,957   33,372 31,690
Reportable Segment | Relutrigine            
Segment Reporting [Line Items]            
Program-specific expenses 13,979   10,509   26,833 15,886
Reportable Segment | Elsunersen            
Segment Reporting [Line Items]            
Program-specific expenses 8,141   1,317   11,338 2,078
Reportable Segment | Other early stage assets            
Segment Reporting [Line Items]            
Program-specific expenses $ 5,471   $ 1,417   $ 8,713 $ 2,522